Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Atox initiates phase II trial of reltecimod in acute kidney injury

May 30, 2018

CLCF1 biomarker may help diagnose delayed graft function in kidney transplantation

May 25, 2018

Novo Nordisk licenses EPGN-696 from Epigen

May 25, 2018

VFMCRP and Cara sign development and commercialization agreement for CR-845

May 23, 2018

FDA approves Lokelma for hyperkalemia

May 22, 2018

Bayer patents new vasopressin V1A and V2 receptor antagonists

May 17, 2018

Dimerix announces plans for phase II trials with DMX-200 in chronic kidney disease

May 16, 2018

Promising in vivo results for EP-055, a potential nonhormonal male contraceptive

May 11, 2018

Astellas licenses rights to Aquinox's rosiptor in Japan and Asia-Pacific countries

May 10, 2018

FDA clears Palladio to begin phase II study of lixivaptan in ADPKD

May 9, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...